Asia-Pacific Insulin Glargine Market Analysis 2012-2017 and Forecast 2018-2023

ReportPage
Report ID
25693
Published Date
09-Mar
No of Report Page
101
Report Category
Pharmaceuticals and Healthcare
Editor's Rating
US $6,600.00
US $6,600.00
US $3,300.00

  • Report Details

    Snapshot
    Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a “peakless” profile (according to the insulin glargine package insert).
    The Asia-Pacific In

    More...
  • Table Of Content

    Table of Content
    1 Industry Overview
    1.1 Insulin Glargine Industry
    1.1.1 Overview
    1.1.2 Development of Insulin Glargine
    1.2 Market Segment
    1.2.1 By Product Type
    1.2.2 By Application
    1.3 Asia-Pacific Overview
    2 Major Companies List
    2.1 Sanofi-Aventis (Company Profile, Products & Services, Sales Data etc.)
    2.2 Ganlee (Company Profile, Products & Se

    More...
  • Inquiry Before Buying
    Inquiry Before Buying -
  • Request Sample
    Request For Sample